Cytokinetics

CYTK

Market cap $7.9B

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I.

Cytokinetics, Incorporated remains a Buy following FDA approval of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM). ORZO's label offers subtle practical advantages over CAMZYOS, notably flexible dosing, enhancing real-world usability. CYTK management targets >50% preference share and increased category penetration to mid-high 20% by the end of 2026, which implies gradual adoption and reliance on assistance programs.

On Friday, the U.S. Food and Drug Administration (FDA) approved Cytokinetics Incorporated's (NASDAQ: CYTK) Myqorzo (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

The U.S. Food and Drug Administration has approved Cytokinetics' drug to treat a rare heart condition, the company said on Friday.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM

Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500.

Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten.